Haemonetics Co. (NYSE:HAE) Short Interest Update

Haemonetics Co. (NYSE:HAE - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totalling 2,040,000 shares, a decline of 6.4% from the March 15th total of 2,180,000 shares. Based on an average daily trading volume, of 455,600 shares, the days-to-cover ratio is presently 4.5 days. Approximately 4.1% of the shares of the stock are sold short.

Haemonetics Price Performance

HAE stock traded down $0.67 during trading on Tuesday, reaching $84.21. 273,091 shares of the company were exchanged, compared to its average volume of 444,185. Haemonetics has a twelve month low of $70.74 and a twelve month high of $95.26. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The company has a market capitalization of $4.28 billion, a price-to-earnings ratio of 34.23, a P/E/G ratio of 2.01 and a beta of 0.36. The company has a 50-day moving average of $78.56 and a two-hundred day moving average of $82.76.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. During the same period in the previous year, the firm posted $0.85 EPS. The company's revenue for the quarter was up 10.1% compared to the same quarter last year. As a group, equities analysts predict that Haemonetics will post 3.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. TheStreet cut shares of Haemonetics from a "b-" rating to a "c+" rating in a research report on Thursday, February 29th. Barrington Research reiterated an "outperform" rating and set a $105.00 price objective on shares of Haemonetics in a research report on Friday. Finally, StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd.

Institutional Investors Weigh In On Haemonetics

A number of institutional investors have recently added to or reduced their stakes in HAE. Capital Research Global Investors grew its holdings in Haemonetics by 166.1% during the 1st quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier's stock worth $344,676,000 after acquiring an additional 3,402,873 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Haemonetics by 21.5% in the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier's stock valued at $389,776,000 after purchasing an additional 1,091,484 shares during the last quarter. Norges Bank bought a new stake in shares of Haemonetics in the 4th quarter valued at $33,932,000. Envestnet Asset Management Inc. boosted its stake in shares of Haemonetics by 1,335.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 406,531 shares of the medical instruments supplier's stock valued at $2,091,000 after purchasing an additional 378,219 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Haemonetics by 224.8% in the 1st quarter. Federated Hermes Inc. now owns 462,586 shares of the medical instruments supplier's stock valued at $29,245,000 after purchasing an additional 320,184 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.